Profil Institute to Present Key Diabetes and Insulin Research at the 50th European Association for the Study of Diabetes Annual Meeting

Profil Institute to Present Key Diabetes and Insulin Research at the 50th European Association for the Study of Diabetes Annual Meeting

SAN DIEGO, September 2, 2014 Profil Institute for Clinical Research, Inc., an early phase clinical research organization (CRO) focused on diabetes and obesity, will present clinical and experimental diabetes and insulin-related research at the European Association for the Study of Diabetes (EASD) 50th Annual Meeting being held September 16-19 in Vienna, Austria.

Poster presentations co-authored by Profil Institute scientists include:

Long-acting basal insulin (HM12470) offers once-weekly dosing potential with a favorable PK, PD and mitogenic profile || Abstract #933
Tuesday, September 16, 2014 – 14:15, Poster Hall
Poster session: The potential future of insulin therapy (074)

Biphasic pharmacokinetic and pharmacodynamic profiles associated with concentrated insulin BIOD-531 show rapid onset and basal duration of action || Abstract #937
Tuesday, September 16, 2014 – 14:15, Poster Hall
Poster session: 074 The potential future of insulin therapy

Automated quantification of brown and white adipose tissue with x-ray computer tomography (CT) and 18F-deoxyglucose positron emission tomography (FDG/PET) || Abstract #661
Wednesday, September 17, 2014 – 13:00, Poster Hall
Poster session: 045 Lipid metabolism in humans

Lipolytic and insulinotropic effects of HM12525A, a novel long-acting GLP-1/glucagon dual agonist || Abstract #866
Thursday, September 18, 2014 – 14:15, Poster Hall
Poster session: 066 Novel therapies

Pharmacological evaluation of once-weekly potentials by combination of long-acting insulin with long-acting exendin4 in an animal model || Abstract #972
Thursday, September 18, 2014 – 14:15, Poster Hall
Poster session: 078 Insulin immunogenicity and kinetics

Panel presentation chaired by Profil Institute’s Dr. Marcus Hompesch:

Novelties in risk prediction (OP 38)
Friday, September 19, 2014 – 10:15 – 11:15, Young Hall

About Profil Institute for Clinical Research, Inc.

Profil Institute for Clinical Research, Inc. is a science driven, early phase clinical research organization (CRO) focused on diabetes and obesity.  It is renowned for its scientific expertise, depth of services, expanded scope of research methodologies, and experience with every clinically relevant drug class in diabetes.  The company provides end-to-end early phase services from consulting for strategic clinical development and regulatory planning through design and completion of complex clinical trials, including the reporting and publication of final study results.

Profil Institute’s expertise and experience encompasses small and large molecule therapies, biologics and biosimilars through all routes of administration, as well as devices.  The company’s clients range from large pharma and drug discovery companies to small virtual companies throughout the Americas, Europe and Asia.

Profil Institute is also recognized internationally as an innovator of methodologies to improve the quality of metabolic research, including its Automated Glucose Clamp technology.  As the leading early phase CRO focused on diabetes and obesity, Profil Institute is driving new, higher standards in metabolic clinical research through collaborative science with key academic and industry partners  and its Metabolic Research Partners™ program.

For more information about Profil Institute, please visit www.profilinstitute.com.

For more information related to Profil Institute’s participation at the EASD Annual Meeting, please contact bd@profilinstitute.com.